ABSTRACT
This chapter presents classification & mode of action, indications & dermatological uses, formulations/presentation, dosages & suggested regimens, baseline investigations, considerations & monitoring, contraindications, cautions, important drug interactions, adverse effects & their management, use in special situations, and essential patient information of Intravenous Immunoglobulin (IVIg). Various modifications have been applied to the original technique of obtaining purified commercial IVIg by ethanolic fractionation of plasma. IVIg is used to treat various autoimmune and infectious diseases, for example idiopathic thrombocytopenic purpura and Kawasaki’s disease. IVIg therapy is usually considered as a second-line therapy when steroids have failed or are contraindicated. Adjuvant therapy with IVIg may be considered for all severe, treatment resistant forms of autoimmune blistering disease. Although the early administration of IVIg in toxic epidermal necrolysis was reported to reverse the progression of skin disease with a favourable outcome some controversy remains about its effectiveness.
